高含量、高韧性玻纤增强PE母料的性能研究与应用

本文研究了以不同PE为基料,再加入高含量玻纤后的改性母料的力学性能以及其应用。结果表明:MI在6⁸左右时树脂与玻纤以及其他相似类型基材的相容性是最好的。其物理力学性能是最高的,而且生产加工比较顺利。对使用该母料的产品的成型周期有很大帮助并满足了产品对型高的要求。     

湿地植物小叶章SSR引物筛选及反应体系优化

开引物发合适的小叶章PCR-SSR引物并建立优化的反应体系是开展小叶章遗传多样性研究的基础。利用正价设计方法对小叶章SSR反应体系中的DNA模板和引物2个反应因素进行了9个水平的优化,并通过温度梯度优化引物退火温度。自主开发了51对小叶章SSR引物,筛选出12对扩增条带清晰、多态性丰富的SSR引物,为小叶章遗传多样性研究提供方法和理论依据。     

脂肪酶催化的研究进展

本文简单介绍了脂肪酶的立体结构和催化机理,综述了非水相的有机溶剂体系中脂肪酶催化的特点与性质,并对微水的无溶剂体系、微乳液体系和超临界体系进行了简单的论述。定向进化技术有助于改善酶的催化特点和应用范围,酶交联晶体的制备和生物印迹方法的采用对提高脂肪酶的活性、热稳定性和选择性也有较大的促进作用。     

无粘结剂分子筛的制备技术

本文介绍了无粘结剂分子筛的制备技术及其特点,并对不同制备方法进行了分析对比,提出了适合我国发展的优势和方向。     

水处理行业的聚合物分散剂的发展现状和研究方向

简述了我国水处理行业现阶段使用的聚合物分散剂的发展现状和研究方向,并对此进行了讨论,就其发展方向提出了作者自己的观点.     

Community governance

American politics, especially at the national level, has become dysfunctional; citizens are deeply frustrated with their political leaders and feel that political institutions are unresponsive and corrupted by entrenched power and money. Government leaders must bear the brunt of this anger and distrust, and subsequently feel a sense of disconnection between themselves and those whom they serve. Ironically, at the same time as the ability of local government to solve problems is severely hindered due to this ‘disconnect,' devolution at the federal and state level is forcing local government to take more and more responsibility for resolving local challenges. This essay argues that the solution to this impasse lies in re-inventing the way communities operate—we need to make a shift from government to governance. The dominant model of local politics, which fit the political landscape of the 1940s–1970s, vested decision making authority solely with governmental leadership; citizens voted and governors governed. This essay describes a new mode of operation, one where non-governmental actors are ‘granted a seat at the table.' In this model the goal of political struggles is no longer to defeat your enemy, but to reach collaborative, consensus-based decisions; government, business, community groups and citizens work together; and leaders share power, working to enable others to decide issues.     

新型生物脱氮途径-厌氧氨氧化研究进展

综述了厌氧氨氧化的反应机理,厌氧氨氧化菌的生活环境,应用于厌氧氨氧化的分子生态学技术,影响厌氧氨氧化过程的因素,以及氮在自然界的全循环途径,展望了厌氧氨氧化的发展趋势。     

Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants

Abstract

Objective: The standard of care for cancer-related venous thromboembolism (VTE) has been low molecular weight heparin (LMWH), but oral anticoagulants are also widely prescribed. This study compared VTE-related healthcare resource utilization and costs of cancer patients treated with anticoagulants.

Methods: Claims data from Humana Database (January 1, 2013–May 31, 2015) were analyzed. Based on the first anticoagulant received, patients were classified into LMWH, warfarin, or rivaroxaban cohorts. Characteristics were evaluated during the 6 months pre-index date (i.e. the first VTE); VTE-related resource utilization and costs were evaluated during follow-up. Cohorts were compared using rate ratios, and p-values and 95% confidence intervals were calculated. Healthcare costs were evaluated per-patient-per-year (PPPY) and compared using mean cost differences.

Results: A total of 2,428 patients (LMWH: n?=?660; warfarin: n?=?1,061; rivaroxaban: n?=?707) were included. Compared to patients treated with LMWH, patients treated with rivaroxaban had significantly fewer VTE-related hospitalizations, hospitalization days, and emergency room and outpatient visits, resulting in an increase of $12,000 VTE-related healthcare costs PPPY with LMWH vs rivaroxaban. Patients treated with rivaroxaban had significantly lower VTE-related resource utilization compared to patients treated with warfarin; however, VTE-related costs were similar between cohorts. The higher drug costs ($1,519) were offset by significantly lower outpatient (?$1,039) and hospitalization costs (?$522) in rivaroxaban relative to the warfarin cohort.

Conclusions: Healthcare resource use and costs associated with VTE treatment in cancer patients are highest with LMWH relative to warfarin and rivaroxaban.     

金属元素改性HMS分子筛的研究进展

中孔HMS（mesoporous molecular sieve）分子筛具有良好的孔道结构，较大的比表面积。因其扩散性能好，水热稳定性高，可广泛用于制备催化剂的载体，或经过引入金属元素改性后，不仅保留了其原有优良的孔道结构，而且赋予其良好的催化活性，可直接用于多类有机合成反应的高效催化剂。文章综述了采用不同金属元素改性的HMS分子筛的基本理化性质，及其在多种类型的催化反应中的应用进展。     

Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer

Aims: Broad molecular profiling of patients with advanced non-small cell lung cancer (NSCLC) is strongly advised to optimize genomic matching with available targeted treatment options or investigational agents. Unlike conventional molecular diagnostic testing, or smaller hotspot panels, comprehensive genomic profiling (CGP) identifies genomic alterations across hundreds of clinically relevant cancer genes from a single tissue specimen. The present study sought to estimate the budget impact of increased use of CGP using a 324-gene panel (FoundationOne) vs non-CGP (represented by a mix of conventional molecular diagnostic testing and smaller NGS hotspot panels) and the number needed to test with CGP to gain 1 life year.

Materials and methods: A decision analytic model was developed to assess the budget impact of increased CGP in advanced NSCLC from a US private payer perspective. Model inputs were based on published literature (epidemiology and treatment outcomes), real-world data (testing and rates, medical service costs), list prices for CGP and anti-cancer drugs, and assumptions for clinical trial participation.

Results: Among 2 million covered lives, 532 had advanced NSCLC; 266 underwent molecular diagnostic testing. An increase in CGP among those tested, from 2% to 10%, was associated with $0.02 per member per month budget impact, of which $0.013 was attributable to costs of prolonged drug treatment and survival and $0.005 to testing cost. Approximately 12 patients would need to be tested with CGP to add 1 life year.

Limitations: The model incorporated certain assumptions to account for inputs with a limited evidence profile and simplify the possible post-CGP treatments.

Conclusions: An increase in CGP utilization from 2% to 10% among patients with advanced NSCLC undergoing molecular diagnostic testing was associated with a modest budget impact, most of which was attributable to increased use of more effective treatments and prolonged survival.